Prestige Consumer Healthcare, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US74112D1019
USD
60.06
-0.22 (-0.36%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Prestige Consumer Healthcare, Inc. stock-summary
stock-summary
Prestige Consumer Healthcare, Inc.
Pharmaceuticals & Biotechnology
Prestige Consumer Healthcare Inc., formerly Prestige Brands Holdings, Inc. is engaged in the marketing, sales and distribution of over-the-counter healthcare products. The Company operates through two segments: North American Over-the-Counter (OTC) Healthcare, and International Over-the-Counter Healthcare. Its portfolio of OTC healthcare products includes core brands, such as DenTek specialty oral care products, Monistat women's health products, Nix lice treatment, Chloraseptic sore throat treatments, Clear Eyes eye care products, Compound W wart treatments, The Doctor's NightGuard dental protector, Little Remedies pediatric over-the-counter products, Efferdent denture care products, Luden's throat drops, Dramamine motion sickness treatment, BC and Goody's pain relievers, Beano gas prevention, Debrox earwax remover, and Gaviscon antacid.
Company Coordinates stock-summary
Company Details
660 White Plains Rd , TARRYTOWN NY : 10591-5139
stock-summary
Tel: 1 914 5246800
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 92 Schemes (59.4%)

Foreign Institutions

Held by 120 Foreign Institutions (6.95%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Ronald Lombardi
Chairman of the Board, President, Chief Executive Officer
Dr. Gary Costley
Lead Independent Director
Mr. John Byom
Independent Director
Mr. Christopher Coughlin
Independent Director
Ms. Sheila Hopkins
Independent Director
Mr. James Jenness
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
250 Million
(Quarterly Results - Jun 2025)
Net Profit:
47 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 3,511 Million (Small Cap)

stock-summary
P/E

20.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.46

stock-summary
Return on Equity

11.94%

stock-summary
Price to Book

1.89